Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus

Journal of Clinical Pharmacology

Volumn 42, Issue 7, 2002, Pages 754-761

  Preston, Richard A ^a,b   Baltodano, Neyton M ^a   Alonso, Alberto B ^a   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Clinical Pharmacology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; POTASSIUM; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; DIAGNOSTIC AGENT; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; URINARY EXCRETION; ADULT; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; URINE; URODYNAMICS;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; COMPARATIVE STUDY; CROSS-OVER STUDIES; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; HUMAN; HYPERTENSION; KIDNEY; LISINOPRIL; POTASSIUM; RECEPTORS, ANGIOTENSIN; SUPPORT, NON-U.S. GOV'T; TETRAZOLES; URODYNAMICS; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 0035998751     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401102696     Document Type: Article

References (43)

1. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population
2. The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)
3. Incidence and prevalence of ESRD
4. Preserving renal function in adults with hypertension and diabetes: A consensus approach
5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
6. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis a randomized controlled trial
7. The role of combination antihypertensive therapy and the progression of renal disease hypertension: Looking toward the next millennium
8. Current strategies for retarding progression of renal disease
9. Renoprotective effects of antihypertensive drugs
10. The beneficial effects of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
11. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
12. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II
13. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study
14. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency
15. Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
16. The angiotensin-converting enzyme inhibitor ramipril slows the rate of GFR decline and the progression to end stage renal failure in proteinuric, non-diabetic chronic renal disease
17. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial
18. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
19. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
20. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease
21. Blood pressure control, proteinuria, and the progression of renal disease
22. Early predictors of 15-year end-stage renal disease in hypertensive patients
23. Blood pressure and end-stage renal disease in men
24. End-stage renal disease in African-American and white men: 16 year MRFIT findings
25. History of hypertension in patients treated for end-stage renal disease
26. Kidney damage in "benign" essential hypertension
27. The role of blood pressure as a risk factor for renal disease: A review of the epidemiologic evidence
28. Hypertension-related renal injury: A major contributor to end-stage renal disease
29. Blood pressure and renal function: Therapeutic implications
30. Long-term effects of antihypertensive agents on proteinuria and renal function
31. Hyperkalemia resulting from captopril administration
32. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: How much should we worry?
33. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
34. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)
35. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
36. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
37. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
38. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
39. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease
40. Randomized trial of losartan versus captopril in patients over 65 with heart failure
41. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
42. Functional impairment in chronic renal disease: III. Studies of potassium excretion
43. Renal response to potassium loading in sickle cell trait